LAUSR

available at http://www.ncbi.nlm.nih.gov/pubmed/29809299 Editorial Comment: A rare and potentially fatal complication of intravesical bacillus Calmette-Gu erin (BCG) therapy is BCG induced sepsis. Historically BCG was not recommended in patients in any type of immunocompromised state for concerns of adverse reaction as well as lack of efficacy. However, more recently support has been proposed regarding BCG efficacy and safety in the transplant population, and it is difficult to find any information on BCG sepsis in patients with solid organ transplantation. Tempering enthusiasm for such a treatment course is at least the hypothetical concern regarding exposing individuals to BCG in an immunocompromised state, as well as this report that outlines a case of BCG induced sepsis more than 7 years after BCG exposure and about 2 years after transplantation. BCG is our standard therapy for patients with intermediate and high risk disease but one should always be cognizant of the possible long-term posttreatment consequences of this immunotherapy.